IASLC North America

Phase III CANOPY Studies to Investigate Canakinumab in NSCLC
October 15, 2019

The agent has a high affinity and specificity for interleukin-1 beta.

Pembrolizumab Shows Benefit for NSCLC Patients with Brain Metastases
October 15, 2019

The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.

Neutrophil-to-Lymphocyte Ratio Helps Predict Survival in Stage III NSCLC
October 12, 2019

NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.